Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 5Head & Neck 3Breast 3Other hematologic neoplasm 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Neoplasms 1Leukoplakia, Oral 1Coproporphyria 1

Interventions

Cisplatin 416Radiotherapy 240Radiotherapy, Intensity-Modulated 178Cetuximab 177Docetaxel 166pembrolizumab 148Carboplatin 121Fluorouracil 113Paclitaxel 90Nivolumab 82Gemcitabine 82Radiation 72Surveys and Questionnaires 71Drug Therapy 70toripalimab 68Surgical Procedures, Operative 64Magnetic Resonance Spectroscopy 63Capecitabine 50Blood Specimen Collection 50Chemoradiotherapy 46Biopsy 44camrelizumab 41durvalumab 40Radiosurgery 40Standard of Care 38Erlotinib Hydrochloride 34nimotuzumab 32130-nm albumin-bound paclitaxel 32tislelizumab 31apatinib 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Sulindac × Head & Neck × Clear all
NCT01515137 2023-03-28

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Pittsburgh

Phase 1 Completed
47 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00299195 2020-11-19

A Randomized Study of Sulindac in Oral Premalignant Lesions

Memorial Sloan Kettering Cancer Center

Phase NA Completed
63 enrolled 10 charts
Head & Neck

Coproporphyria, Leukoplakia, Oral, Neoplasms

NCT00392665 2017-04-13

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Massachusetts General Hospital

Phase 2 Terminated
36 enrolled 10 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡